Spots Global Cancer Trial Database for AASUR in High Risk Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AASUR in High Risk Prostate Cancer
Official Title: ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
Study ID: NCT02772588
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
John Hopkins Medical Center, Baltimore, Maryland, United States
University of Michigan Health System, Ann Arbor, Michigan, United States
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Weill Cornell Medical Center, New York, New York, United States
Memorial Sloan Kettering Rockville, Rockville Centre, New York, United States
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Contact Details
Name: Sean M McBride, MD, MPH
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
